The Rapidly Evolving Landscape of Hormone Medicine
Hormone therapy in 2026 looks dramatically different from even five years ago — and the pace of innovation is accelerating. From novel delivery systems and more selective receptor molecules to sophisticated biomarker panels and AI-driven protocol optimization, the tools available to patients and providers in hormone optimization are expanding rapidly. Here is an overview of the most clinically significant advances shaping the field.
Oral Testosterone for Men
The FDA approval of testosterone undecanoate oral soft gel capsules (Jatenzo, Tlando) has added a meaningful delivery option for men who prefer not to inject or apply topical testosterone. Unlike earlier oral testosterone formulations that caused significant liver toxicity due to first-pass metabolism, the new oral formulations use lymphatic absorption to bypass hepatic first-pass processing. While not yet as widely used as injectable or transdermal formulations due to cost and twice-daily dosing requirements, oral TRT represents a meaningful option for specific patient profiles.
Next-Generation Selective Androgen Receptor Modulators (SARMs)
SARMs — compounds that selectively activate androgen receptors in specific tissues (muscle, bone) while minimizing androgenic effects in others (prostate, skin, hair follicles) — have been under clinical development for decades with promising animal data but inconsistent and often disappointing human trial results. However, several newer SARM candidates are in advanced clinical trials for sarcopenia, frailty, and osteoporosis — with potential to provide anabolic benefits in muscle and bone without the prostate and cardiovascular considerations of testosterone. This remains an area to watch rather than a current clinical reality for most patients.
Continuous Glucose and Metabolic Monitoring Integration
Continuous glucose monitors (CGMs) — previously available only by prescription for diabetic patients — have become accessible to broader wellness-oriented populations. Integration of CGM data with hormone therapy monitoring allows real-time assessment of how hormone changes affect glucose metabolism, insulin sensitivity, and metabolic dynamics — providing a far richer picture of metabolic health optimization than quarterly fasting labs alone.
Expanded Peptide Pharmacopeia
The peptide therapy toolkit continues to expand with several compounds moving from research into clinical use: AOD-9604 (a fragment of growth hormone with specific fat-burning properties), MOTS-c (a mitochondria-derived peptide with remarkable metabolic and longevity effects in animal models), epithalon (a pineal peptide with telomere-lengthening and lifespan-extending data in animal research), and various kisspeptin analogs being investigated for HPG axis restoration without the fertility suppression of TRT.
AI-Driven Protocol Optimization
Machine learning tools are beginning to assist hormone therapy providers by analyzing patterns across large patient datasets to predict optimal starting doses, identify likely side effect profiles before they occur, and suggest protocol adjustments based on lab trends and symptom patterns. These tools do not replace clinical judgment — they augment it with pattern recognition across populations far larger than any individual clinician’s experience.
What Multigen Wellness Is Watching
At Multigen Wellness, we actively monitor the clinical literature and adapt protocols as evidence-based advances emerge. Our commitment is always to the most current, evidence-supported practices — adopting innovations when their clinical evidence supports them, rather than marketing trends before evidence exists.
To be part of a cutting-edge hormone optimization practice that stays current with the field, call Multigen Wellness at (800) 259-0015.